Enterprise Value
482.7M
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
2.36%
Insider Ownership
0.19%
Institutional Own.
34.47%
Qtr Updated
09/30/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
FOTIVDA (Tivozanib) (VEGFR 123 TKI) Details Kidney cancer, Carcinoma , Genetic disorder, Rare genetic disease, Renal cell carcinoma | Approved Quarterly sales |